

Imaavy™ (nipocalimab-aahu) (Intravenous)

Document Number: M-0797

Last Review Date: 06/05/2025

Date of Origin: 06/05/2025

Dates Reviewed: 06/2025

I. Length of Authorization ¹

- Initial: Prior authorization validity will be provided initially for 6 months.
- Renewal: Prior authorization validity may be renewed every 12 months thereafter.

II. Dosing Limits

Max Units (per dose and over time) [HCPCS Unit]:

- 3,600 mg initially then 1,800 mg every two weeks thereafter

III. Initial Approval Criteria ¹

Coverage is provided in the following conditions:

- Patient is at least 12 years of age; **AND**
- Patient is up to date with all vaccinations, in accordance with current vaccination guidelines, prior to initiating therapy; **AND**

Universal Criteria ^{1,3}

- Will not be used in combination with other immunomodulatory biologic therapies; **AND**
- Patient will avoid or use with caution medications known to worsen or exacerbate symptoms of myasthenia gravis (MG) (e.g., certain antibiotics, beta-blockers, botulinum toxins, hydroxychloroquine, etc.); **AND**
- Will not be administered with live-attenuated or live vaccines during treatment; **AND**
- Patient does not have an active infection, including clinically important localized infections; **AND**

Generalized Myasthenia Gravis (gMG) † Φ ^{1,3-6,8}

- Patient has Myasthenia Gravis Foundation of America (MGFA) Clinical Classification of Class II to IV disease §; **AND**
- Patient has a positive serologic test for anti-acetylcholine receptor (AChR) or anti-muscle-specific tyrosine kinase (MuSK) antibodies; **AND**
- Patient has had a thymectomy (*Note: Applicable only to patients with AChR positive disease and with thymomas OR non-thymomatous patients who are 50 years of age or younger*); **AND**

- Physician has assessed objective signs of neurological weakness and fatiguability on a baseline neurological examination (e.g., including, but not limited to, the Quantitative Myasthenia Gravis (QMG) score, etc.); **AND**
- Patient has a baseline MG-Activities of Daily Living (MG-ADL) total score of at least 6; **AND**
 - Patient had an inadequate response to initial therapy based on their antibodies:
 - AChR+ disease: a minimum one-year trial of concurrent use with an oral corticosteroid plus another immunosuppressive therapy (e.g., azathioprine, cyclosporine, mycophenolate, etc.); **OR**
 - MuSK+ disease: a minimum one-year trial with immunosuppressive therapy (e.g., corticosteroids, azathioprine, or mycophenolate) and rituximab; **OR**
 - Patient required at least one acute or chronic treatment with plasmapheresis or plasma exchange (PE) or intravenous immunoglobulin (IVIG) in addition to immunosuppressant therapy

† FDA Approved Indication(s); ‡ Compendia Recommended Indication(s); Ⓢ Orphan Drug

§ Myasthenia Gravis Foundation of America (MGFA) Disease Clinical Classification: ^{5,6}

- **Class I**: Any ocular muscle weakness; may have weakness of eye closure. All other muscle strength is normal.
- **Class II**: Mild weakness affecting muscles other than ocular muscles; may also have ocular muscle weakness of any severity.
 - **IIa**. Predominantly affecting limb, axial muscles, or both. May also have lesser involvement of oropharyngeal muscles.
 - **IIb**. Predominantly affecting oropharyngeal, respiratory muscles, or both. May also have lesser or equal involvement of limb, axial muscles, or both.
- **Class III**: Moderate weakness affecting muscles other than ocular muscles; may also have ocular muscle weakness of any severity.
 - **IIIa**. Predominantly affecting limb, axial muscles, or both. May also have lesser involvement of oropharyngeal muscles.
 - **IIIb**. Predominantly affecting oropharyngeal, respiratory muscles, or both. May also have lesser or equal involvement of limb, axial muscles, or both.
- **Class IV**: Severe weakness affecting muscles other than ocular muscles; may also have ocular muscle weakness of any severity.
 - **IVa**. Predominantly affecting limb, axial muscles, or both. May also have lesser involvement of oropharyngeal muscles.
 - **IVb**. Predominantly affecting oropharyngeal, respiratory muscles, or both. May also have lesser or equal involvement of limb, axial muscles, or both.
- **Class V**: Defined as intubation, with or without mechanical ventilation, except when employed during routine postoperative management. The use of a feeding tube without intubation places the patient in class IVb.

IV. Renewal Criteria ¹

Coverage can be renewed based upon the following criteria:

- Patient continues to meet the universal and other indication-specific relevant criteria identified in section III; **AND**
- Absence of unacceptable toxicity from the drug. Examples of unacceptable toxicity include: infection, severe hypersensitivity reactions (e.g., anaphylaxis, angioedema, etc.), etc.; **AND**

- Patient has had an improvement (i.e., reduction) of at least 1-point from baseline in the Myasthenia Gravis-Specific Activities of Daily Living scale (MG-ADL) total score **Δ**; **AND**
 - Improvement in muscle strength testing with fatigue maneuvers as evidenced on neurologic examination when compared to baseline
- (**Δ** May substitute an improvement of at least 1-point from baseline in the Quantitative Myasthenia Gravis (QMG) total score, if available)

V. Dosage/Administration ¹

Indication	Dose
Generalized Myasthenia Gravis (gMG)	The recommended initial dosage of Imaavy is 30 mg/kg administered once via intravenous infusion over at least 30 minutes. Two weeks after the initial dosage administer a maintenance dosage of 15 mg/kg via intravenous infusion over at least 15 minutes. Continue the maintenance dosage every two weeks thereafter.

VI. Billing Code/Availability Information

HCPCS Code:

- J3590 – Unclassified biologics
- C9399 – Unclassified drugs or biologicals (*Hospital Outpatient Use Only*)

NDC(s):

- Imaavy 300 mg/1.62 mL solution in a single-dose vial: 57894-0800-xx
- Imaavy 1,200 mg/6.5 mL solution in a single-dose vial: 57894-0801-xx

VII. References

1. Imaavy [package insert]. Horsham, PA; Janssen Biotech, Inc., April 2025. Accessed May 2025.
2. Sussman J, Farrugia ME, Maddison P, et al. Myasthenia gravis: Association of British Neurologists' management guidelines. *Pract Neurol* 2015; 15: 199-206.
3. Narayanaswami P, Sanders D, Wolfe G, Benatar M, et al. International consensus guidance for management of myasthenia gravis, 2020 update. *Neurology*® 2021;96:114-122. doi:10.1212/WNL.00000000000011124.
4. Antozzi C, Vu PT, Ramchandren S, et al. Safety and efficacy of nipocalimab in adults with generalised myasthenia gravis (Vivacity-MG3): a phase 3, randomised, double-blind, placebo-controlled study. *The Lancet Neurology*, Volume 24, Issue 2, 105 - 116
5. Jayam-Trouth A, Dabi A, Solieman N, Kurukumbi M, Kalyanam J. Myasthenia gravis: a review. *Autoimmune Dis.* 2012;2012:874680. doi:10.1155/2012/874680
6. Bril V, Druzdz A, Grosskreutz J, et al. Long-term Efficacy and Safety of Symptom-driven Cyclic Rozanolixizumab Treatment in Patients with Generalized Myasthenia Gravis: A Pooled Analysis of a Phase 3 Study and Two Open-label Extension Studies (P1-5.012). *Neurology* Apr 2023, 100 (17 Supplement 2) 3747; DOI: 10.1212/WNL.0000000000203497

7. Guidon AC, Muppidi S, Nowak RJ, et al. Telemedicine visits in myasthenia gravis: expert guidance and the Myasthenia Gravis Core Exam (MG-CE). Muscle Nerve 2021; 64:270-276
8. Gronseth GS, Barohn R, Narayanaswami P. Practice advisory: Thymectomy for myasthenia gravis (practice parameter update): Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology. Neurology. 2020;94(16):705. Epub 2020 Mar 25.

Appendix 1 – Covered Diagnosis Codes

ICD-10	ICD-10 Description
G70.00	Myasthenia gravis without (acute) exacerbation
G70.01	Myasthenia gravis with (acute) exacerbation

Appendix 2 – Centers for Medicare and Medicaid Services (CMS)

The preceding information is intended for non-Medicare coverage determinations. Medicare coverage for outpatient (Part B) drugs is outlined in the Medicare Benefit Policy Manual (Pub. 100-2), Chapter 15, §50 Drugs and Biologicals. In addition, National Coverage Determinations (NCDs) and/or Local Coverage Determinations (LCDs) may exist and compliance with these policies is required where applicable. Local Coverage Articles (LCAs) may also exist for claims payment purposes or to clarify benefit eligibility under Part B for drugs which may be self-administered. The following link may be used to search for NCD, LCD, or LCA documents: <https://www.cms.gov/medicare-coverage-database/search.aspx>. Additional indications, including any preceding information, may be applied at the discretion of the health plan.

Medicare Part B Covered Diagnosis Codes (applicable to existing NCD/LCD/LCA): N/A

Medicare Part B Administrative Contractor (MAC) Jurisdictions		
Jurisdiction	Applicable State/US Territory	Contractor
E (1)	CA, HI, NV, AS, GU, CNMI	Noridian Healthcare Solutions, LLC
F (2 & 3)	AK, WA, OR, ID, ND, SD, MT, WY, UT, AZ	Noridian Healthcare Solutions, LLC
5	KS, NE, IA, MO	Wisconsin Physicians Service Insurance Corp (WPS)
6	MN, WI, IL	National Government Services, Inc. (NGS)
H (4 & 7)	LA, AR, MS, TX, OK, CO, NM	Novitas Solutions, Inc.
8	MI, IN	Wisconsin Physicians Service Insurance Corp (WPS)
N (9)	FL, PR, VI	First Coast Service Options, Inc.
J (10)	TN, GA, AL	Palmetto GBA
M (11)	NC, SC, WV, VA (excluding below)	Palmetto GBA
L (12)	DE, MD, PA, NJ, DC (includes Arlington & Fairfax counties and the city of Alexandria in VA)	Novitas Solutions, Inc.
K (13 & 14)	NY, CT, MA, RI, VT, ME, NH	National Government Services, Inc. (NGS)
15	KY, OH	CGS Administrators, LLC